Jaguar Animal Health, Inc. (NASDAQ:JAGX) Sees Significant Decrease in Short Interest

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the target of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 327,563 shares, a drop of 15.1% from the February 12th total of 386,035 shares. Based on an average trading volume of 392,756 shares, the short-interest ratio is currently 0.8 days. Approximately 9.5% of the shares of the stock are short sold. Approximately 9.5% of the shares of the stock are short sold. Based on an average trading volume of 392,756 shares, the short-interest ratio is currently 0.8 days.

Jaguar Animal Health Trading Up 5.0%

Shares of NASDAQ JAGX traded up $0.03 during trading hours on Monday, hitting $0.53. The company’s stock had a trading volume of 50,958 shares, compared to its average volume of 4,607,771. The company has a debt-to-equity ratio of 4.08, a quick ratio of 0.52 and a current ratio of 0.81. The stock has a market cap of $1.97 million, a price-to-earnings ratio of -0.02 and a beta of 0.02. Jaguar Animal Health has a 12 month low of $0.46 and a 12 month high of $15.48. The business has a 50-day simple moving average of $0.74 and a 200-day simple moving average of $1.34.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Jaguar Animal Health to a “strong sell” rating in a research report on Friday, January 23rd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Jaguar Animal Health has a consensus rating of “Hold” and a consensus price target of $60.00.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.